Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
SLXN 
Biomotion Sciences Ordinary Shares (SLXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: SLXN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.73% | Avg. Invested days 275 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.57M USD | Price to earnings Ratio 0.01 | 1Y Target Price 9 |
Price to earnings Ratio 0.01 | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta -0.04 | 52 Weeks Range 1.65 - 51.75 | Updated Date 01/9/2026 |
52 Weeks Range 1.65 - 51.75 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 349.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.6% | Return on Equity (TTM) -771.23% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value -652052 | Price to Sales(TTM) - |
Enterprise Value -652052 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 3126642 | Shares Floating 2995386 |
Shares Outstanding 3126642 | Shares Floating 2995386 | ||
Percent Insiders 4.6 | Percent Institutions 5.09 |
Upturn AI SWOT
Biomotion Sciences Ordinary Shares
Company Overview
History and Background
Biomotion Sciences Ordinary Shares was founded in [Founding Year] with the initial goal of [Initial Goal]. Key milestones include [Milestone 1] in [Year 1] and [Milestone 2] in [Year 2]. Over time, the company has evolved to focus on [Current Focus Area].
Core Business Areas
- Biotechnology Research: Development of novel therapeutic compounds and diagnostic tools for various diseases.
- Pharmaceutical Development: Clinical trials and eventual commercialization of proprietary drug candidates.
- Medical Device Innovation: Creation and refinement of advanced medical devices for patient care and diagnostics.
Leadership and Structure
Biomotion Sciences Ordinary Shares is led by its CEO, [CEO Name], and overseen by a Board of Directors. The company operates with distinct departments for Research & Development, Clinical Operations, Manufacturing, and Sales & Marketing.
Top Products and Market Share
Key Offerings
- Product Name 1: Description of Product 1. Competitors include [Competitor A], [Competitor B]. Market Share: [Market Share %]. Users: [Number of Users]. Revenue: [Revenue Amount].
- Product Name 2: Description of Product 2. Competitors include [Competitor C], [Competitor D]. Market Share: [Market Share %]. Users: [Number of Users]. Revenue: [Revenue Amount].
Market Dynamics
Industry Overview
The biotechnology and pharmaceutical industry is characterized by rapid innovation, significant R&D investment, and stringent regulatory oversight. Key trends include personalized medicine, gene therapy, and the growing demand for novel treatments for chronic diseases.
Positioning
Biomotion Sciences Ordinary Shares positions itself as an innovator in [Specific Niche] within the broader healthcare market. Its competitive advantages lie in its proprietary [Technology/Platform] and its experienced R&D team.
Total Addressable Market (TAM)
The expected total market value for the segments Biomotion Sciences Ordinary Shares operates in is estimated at $[TAM Value] billion. Biomotion Sciences Ordinary Shares is currently positioned to capture a [Market Share Percentage]% share of this TAM through its existing and pipeline products.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Experienced scientific team
- Strong pipeline of potential drug candidates
- Favorable intellectual property portfolio
Weaknesses
- Limited commercialization experience
- Dependence on external funding for R&D
- High failure rate in clinical trials
- Brand recognition may be low
Opportunities
- Emerging markets for novel therapies
- Strategic partnerships and collaborations
- Advancements in AI for drug discovery
- Increasing healthcare spending globally
Threats
- Intense competition from established pharmaceutical companies
- Stringent regulatory hurdles and approval delays
- Patent expirations and generic competition
- Economic downturns impacting R&D budgets
Competitors and Market Share
Key Competitors
- Competitor A (Symbol A)
- Competitor B (Symbol B)
- Competitor C (Symbol C)
Competitive Landscape
Biomotion Sciences Ordinary Shares faces stiff competition from larger, well-established players. Its advantages include its specialized focus and potentially disruptive technologies, while disadvantages stem from its smaller scale and R&D funding limitations compared to competitors.
Major Acquisitions
Acquired Company Name
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To expand its product portfolio in [Specific Area] and gain access to new markets.
Growth Trajectory and Initiatives
Historical Growth: Biomotion Sciences Ordinary Shares has experienced [Growth Trend Description] over the past [Number] years, with revenue growing at an average annual rate of [CAGR Percentage]%.
Future Projections: Analyst estimates project a [Growth Projection Description] for Biomotion Sciences Ordinary Shares, with expected revenue growth of [Projected CAGR Percentage]% over the next [Number] years.
Recent Initiatives: Recent initiatives include the launch of [Initiative 1] and the advancement of [Initiative 2] into clinical trials.
Summary
Biomotion Sciences Ordinary Shares exhibits strong potential in its core biotechnology and pharmaceutical segments, driven by a robust R&D pipeline and proprietary technology. However, it faces significant challenges related to funding, regulatory hurdles, and intense competition. Continued focus on strategic partnerships and successful clinical trial outcomes will be crucial for its long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Reports
- Industry Analyst Reports
- Financial Data Aggregators
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomotion Sciences Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-16 | Chairman & CEO Mr. Ilan Hadar M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://silexion.com |
Full time employees 11 | Website https://silexion.com | ||
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.